Edith A. Perez, MD, Breast Cancer: Giant of Cancer Care; deputy director at large, Mayo Clinic Cancer Center, Serene M. and Frances C. Durling professor of Medicine, Division of Hematology/Oncology, discusses a genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.
Edith A. Perez, MD, Breast Cancer: Giant of Cancer Care; deputy director at large, Mayo Clinic Cancer Center, Serene M. and Frances C. Durling professor of Medicine, Division of Hematology/Oncology, discusses a genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.
Clinical Pearls:
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Durability and Intracranial Efficacy Observed With T-DXd in HER2+ MBC
January 13th 2025During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed how the outcomes of the DESTINY-Breast03 and other trials impact treatment of metastatic HER2-positive breast cancer in the second article of a 2-part series.
Read More